TRIREGOL Coated Tablets
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
02-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ETHINYLESTRADIOL LEVONORGESTREL ETHINYLESTRADIOL LEVONORGESTREL ETHINYLESTRADIOL LEVONORGESTREL
Available from:
Medimpex France SA
Pharmaceutical form:
Coated Tablets
Authorization date:
2005-02-11
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Triregol coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
6 pink tablets: each tablet contains 50 microgram levonorgestrel and 30 microgram ethinylestradiol
5 white tablets: each tablet contains 75 microgram levonorgestrel and 40 microgram ethinylestradiol
10 ochre tablets: each tablet contains 125 microgram levonorgestrel and 30 microgram ethinylestradiol
Each tablet contains 33 mg of lactose monohydrate and 22 mg of sucrose.
For full list of excipients, _see section 6.1._
3 PHARMACEUTICAL FORM
Coated tablet.
Pink, bright, biconvex, circular tablets
White, bright, biconvex, circular tablets
Ochre, bright, biconvex, circular tablets
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Oral contraception
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
How is triregol taken?
The tablets must be taken in the order directed on the pack every day at approximately the same time of the day. One
tablet daily is taken for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval ; during
which time a withdrawal bleed usually occurs. This bleeding will usually begin on the 2nd or 3rd day after ingestion of
the last tablet and it may not have ceased, before the next pack is started.
How to start triregol
_No preceding intake of hormonal contraceptives (within the last month)_
The tablet intake should start on day 1 in the woman's normal cycle (i.e. On the first day on which the woman has a
menstrual bleeding). Starting intake on day 2-5 is allowed, but during the first cycle the concurrent use of barrier
method during the first 7 days of tablet intake is advisable.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________
Read the complete document
